POSTER INDEX

POSTER GALLERY - EXHIBIT HALL
VIRTUAL ePOSTER GALLERY

Biomedical/ Coagulation research

POSTER #	TITLE	PRESENTING AUTHOR
MP-001	F8 Mutation spectrum in a large cohort of Hemophilia A patients from an Italian Regional Reference Centre: an update	Federica Riccardi
PP-001	Genetic etiology of a cohort of Uruguayan hemophilic patients and carriers	Yasser Vega
PP-002	Molecular insights into the mechanism of large F9 deletions in three families with severe hemophilia B	Liliana Rossetti
PP-003	Unleashing the power of large language models specific for hemophilia research	Tiago Jose da Silva Lopes
PP-004	Detection of intron 1 and 22 inversions in the factor VIII gene by IS-PCR modified by capillary electrophoresis in patients and carriers of severe hemophilia A	Rosa Martínez-Contreras
PP-005	Dominant negative effects of Gln50Arg mutation in the EGF-1 domain of factor IX causes severe Hemophilia B that negatively affects factor IX replacement therapy	Tirsa van duijl
PO-001	The effects of Laennec, Immune Alpha One, and Dipeptivene on factor VIII activity and thrombin generation - in vitro	HongHoe Koo
PO-002	In silico evaluation of Danazol for bleeding disorders: The good, the bad and the ugly	Yara Pires

Capacity building/ Advocacy and outreach models

POSTER #	TITLE	PRESENTING AUTHOR
MP-002	KOHEM summer camp, recovery of Korea bleeding disorder community after the pandemic	Nam-Il Lee
MP-003	PACT - Bridging Hemophilia Care Gaps	lubna zafar
MP-004	Development of an online educational case-based tool to supplement hematology trainee understanding of hemostatic disorders and their management.	Kelsey Uminski
MP-005	Being a patient researcher for one day: an original proposition to celebrate the World Haemophilia Day	Thomas Sannié
MP-006	It's Now: The Place of Youth in Hemophilia Spaces	Mateo Palladino

Capacity building/ Advocacy and outreach models

POSTER #	TITLE	PRESENTING AUTHOR
MP-007	Driving an educational programme for teenagers living with haemophilia: importance of a partnership between AFH resource patients and healthcare professionals	Thomas Sannié
MP-009	Building the future of advocacy: Uruguay's inclusion of young leaders	Juan Andres Pereira de Souza
MP-010	Social media strategy as a key to success in NMO advocacy plans/campaigns: Uruguay best practice	Mathias Guerreiro
MP-011	Outreach and advocacy activities of the Senegalese Hemophilia Association	Abdoulaye Loum
PP-006	CATALYZING CARE: The Inauguration of Quetta Chapter under WFH-PACT	Masood Fareed Malik
PP-007	Permanent Training Center in Hemophilia “Hnos. Manuel and Javier Moreno”	Javier Montoya Nicolas
PP-008	Educational and informative materials for primary care health professionals, affected and families	Javier Montoya Nicolas
PP-009	Effectiveness of the National Bleeding Disorders Foundation support of state chapter advocacy programs	Nathan Schaefer
PP-010	Formation of leaders in the Americas: results of the strategic alliance	Antonio Gomez Cavallini
PP-011	Hemophilia A Rapid card testing in outreach programs: Experience from a single tertiary care centre in Kerala	Bitty Kurian
PP-012	A pilot study on the effectiveness of the World Federation of Hemophilia (WFH) Shared Decision-Making (SDM) Tool	Donna Coffin
PP-204	Lecture for university students as a way to increase knowledge about coagulopathies	Francisco Careta
PP-205	Health education needs in hematological orphan diseases for sick people and caregivers in Ibagué, Tolima, Colombia	Nadia Perdomo
PO-003	My opinion	Tania Pietrobelli
PO-004	Equality, it’s in our blood	Mark Ward

Care delivery

POSTER #	TITLE	PRESENTING AUTHOR
MP-013	Three years of achievements and challenges in care of people with moderate haemophilia: results from a nationwide registry	Sergio Cáceres
MP-014	Implementation of home therapy in Mauritius	Janaki Sonoo
MP-015	Quality improvement initiative involving electronic health records to improve the safety of bleeding disorder patients in the emergency department	Nancy Hodgson
PP-013	Assessment of Canadian standards of care	David Page
PP-014	Introduction of an outpatient pathway for ankle arthrodesis surgery for people with severe haemophilia	Deirdre Gorman
PP-015	Emicizumab: Real world experience from a single center	lubna zafar
PP-016	Healthcare professionals' view on the use-case scenarios for point-of-care testing in hemophilia A patients in a home-setting	Aernoud Bavinck
PP-017	Overview of medical care and support for patients living with haemophilia in the Democratic Republic of Congo, Kinshasa in 2023	Jonathan Kukila
PP-018	Progress in hemophilia care in the Democratic Republic of Congo from 2017 to today.	Gueth Kundabi Akoto
PP-019	Real world challenges in the management of hemophilia with significant co-morbidities	Suchitra Sivadas
PP-206	Prevalence of osteoporosis in hemophilia patients in Jamnagar, India	Bhadresh Vyas
PP-207	Mobile service unit for people with hemophilia	Meera Hanagavadi
PO-005	Cocreating to improve patient experience in a pediatric hemophilia unit	Rubén Berrueco
PO-006	Care models in the management of bleed events in persons with hemophilia in Western Kenya	Nancy Midiwo
PO-007	The development and expansion of the nurse-led genetic counselling service for female carriers	Janet Cleary
PO-008	Patient and caregiver preferences for hemophilia A treatment in Taiwan: A discrete choice Experiment	Jiaan-Der Wang
PO-009	Use of drugs in the management of Malagasy patients with hemophilia	Olivat Aimée Rakoto Alson
PO-010	Satisfaction survey for people with hemophilia (PWH)	Kaouther Zahra
PO-011	Assessment of access to factor VIII and factor IX to persons with Hemophilia during emergencies: a quality improvement study	Kara Burge

Clinical research and clinical trials

POSTER #	TITLE	PRESENTING AUTHOR
MP-016	"Low-dose Prophy" and chemical synovectomy : A new concept of optimal prophylaxis to preserve joint health for severe hemophilic patients living in resource-limited countries	Laurent Frenzel
MP-018	Active lifestyle in patients with haemophilia A or B with and without inhibitors on once-daily subcutaneous concizumab prophylaxis: Results from the phase 3 explorer7 and explorer8 trials	Víctor Jiménez-Yuste
PP-020	Epidemiology of initial severe bleeding revealing a rare bleeding disorder: a francecoag network study	Sandrine Meunier
PP-021	Summercamp for children with hemophilia in Murcia (2023)	Sara Caracena López
PP-022	Real experience of prophylaxis with emicizumab in patients with congenital hemophilia A with and without FVIII inhibitors in the HCUVA	Ángela Heredia Cano
PP-023	Evolution of patient profile in the last twenty years in the Summercamp La Charca	Ángela Heredia Cano
PP-024	Real-world effectiveness and safety of damoctocog alfa pegol in patients with haemophilia A and a history of factor VIII inhibitors: a post-hoc analysis of the ongoing HEM-POWR study	María Teresa Álvarez-Román
PP-025	Real-world effectiveness of pegylated, recombinant antihemophilic factor (rurioctocog alfa pegol) prophylaxis in patients with hemophilia A in Canada: A retrospective, intra-patient comparison with a before-after design	Arun Keepanasseril
PP-026	Self-reflections, lessons learned, and suggestions for data quality assurance from a retrospective data analysis from the Canadian Bleeding Disorders Registry.	Alfonso Iorio
PP-027	The disruptive impact of extensive adoption of emicizumab on the clinical validation of new therapeutic agents in hemophilia A	Cedric Hermans
PO-012	Retrospective observational case-control study on survival and bleeding incidents after placement of dental implants in patients with hereditary coagulation disorders: 2-years evolution	Lizett Castellanos Cosano
PO-013	Three-year interim analysis results of AOZORA study	Midori Shima
PO-014	Real-world data on treatment regimen and medical use among patients with hemophilia B in South Korea	Eun Jin Choi
PO-015	Efanesoctocog alfa treatment for children below 12 years of age with severe haemophilia A: A plain language summary of the XTEND-Kids study	María Teresa Álvarez-Román
PO-016	Safety, tolerability, pharmacokinetics and pharmacodynamics of Mim8 in patients with haemophilia A: FRONTIER1 extension	Pratima Chowdary
PO-017	Assessment of Azerbaijan model of treatment of hemophilia according to demand	Mehpara Kazimova
PO-018	A natural history cohort study of the safety, effectiveness, and practice of treatment in people with non-neoplastic hematologic disorders	Tammuella Chrisentery-Singleton

Comorbidities

POSTER #	TITLE	PRESENTING AUTHOR
PP-028	Management of persons with inherited hemophilia requiring antithrombotic therapy: A Canadian modified Delphi Study	Kelsey Uminski
PP-029	Application of self-monitoring smart devices to improve the health status in hemophiliacs	Soyon Kim
PP-030	Non-invasive evaluation of arterial stiffness and characterization of cardiovascular risk factors in a patients with hemophilia cohort in Uruguay	Joaquín Ferreira
PO-019	Clinical profile and cardiovascular risk factors among hemophilians followed at university clinics of Kinshasa	Gueth Kundabi Akoto

Data and demographics

POSTER #	TITLE	PRESENTING AUTHOR
MP-019	Prevalence of venous thromboembolism in people with inherited bleeding disorders: Real world data from the ATHNdataset	Shreya Agarwal
MP-020	Biliary disorders among people with hemophilia: Findings from a case-control claims analysis	Steven Pipe
MPE-064	Incidence rates of arterial and venous thrombosis among people with hemophilia A or B	Guy Young
PP-031	Bleeding patterns and clotting factor concentrates utilisation in haemophilia patients treated at Kamuzu Central Hospital, Malawi	Francis Mkwenembera
PP-032	Evaluation of quality of life and problems of access to healthcare services in patients with hemophilia	Caner Dadak
PP-033	Clinicohematological profile of hemophilia patients at a tertiary care center in Eastern India	Ruchi Sinha
PP-034	Enrollment of Malagasy patients with hemophilia in the World Bleeding Disorders Registry	Tantely Randriamandrato
PP-035	Case series: Acquired hemophilia in Colombian patients	Sandro Parra Soto
PP-036	The follow up report on the demographics and clinical findings from the Korean bleeding disorder registry	Eun Jin Choi
PP-037	Socio-economic determinants and their impact on patients and families living with Hemophilia in a low- and middle-income country: An experience from a tertiary care center in Northern India	Pragya Kafley
PP-038	Exploring the relationship between economic development and underreported bleeding disorders	Richard Kelly

Data and demographics

POSTER #	TITLE	PRESENTING AUTHOR
PP-040	Sociodemographic profile and socioeconomic level of patients at the Monterrey hemophilia care center, an inside look at the families	Laura Páez
PP-042	Exploring varied clinical profiles in mild hemophilia: Insights from the Castilla-La Mancha, Spain Hemophilia Registry	Sonia Herrero
PP-043	Five-year analysis of laboratory services in hemostasis from a resource-limited setting: Experience from a single tertiary care center in Kerala, Southern India	Bitty Kurian
PP-044	Exploring the clinical spectrum of factor VII deficiency in India: a retrospective study	Gohul Jalajakumari
PP-045	Evolution of hemophilia care: analyzing factor VIII usage trends and the impact of novel therapies	Ellia Tootoonchian
PP-046	Factors associated with delayed diagnostic of inherited bleeding disorders in LMIC	Saliou Diop
PP-047	Population pharmacokinetics in hemophilia: Availability and implementation in Latin-America. Results of the CLAHT-WFH survey	Jesus Ardila Novoa
PP-048	Clinical characteristics and therapeutic management of confirmed hemophilia cases registered in the hemophilia treatment center at the Rajshahi in Bangladesh	M. Morsed Zaman Miah
PP-049	Factor VIII in female patients with hemophilia A (PwH): A laboratory analysis	Gloria Ramos
PO-020	Direct data transfer of people with hereditary bleeding disorders from the Hereditary Bleeding Disorder Registry in Thailand to the World Bleeding Disorders Registry and the Annual Global Survey of the World Federation of Hemophilia	Ampaiwan Chuansumrit

Gene therapy

POSTER #	TITLE	PRESENTING AUTHOR
MP-021	Global efforts in uniting all stakeholders, including regulatory agencies, in ensuring safety of hemophilia gene therapy patients: the World Federation of Hemophilia Gene Therapy Registry	Mayss Naccache
MP-022	Haemophilia Gene therapy: a proposed structure, process and timeline for patient discussion for a truly informed decision	Enrico Ferri Grazzi
MP-023	Clinical efficacy of interventions for adult patients with moderately severe to severe hemophilia B: An indirect treatment comparison with fidanacogene elaparvovec	Valeria Merla
MP-024	Value contribution of etranacogene dezaparvovec for the treatment of severe and moderately severe haemophilia B in Spain through Multicriteria Decision Analysis (MCDA)	Daniel-Anibal García Diego

Gene therapy

POSTER #	TITLE	PRESENTING AUTHOR
MPE-065	Adults with haemophilia B and history of chronic HCV/HBV infection receiving etranacogene dezaparvovec gene therapy in the HOPE-B clinical trial demonstrate long-term bleeding protection and sustained FIX Activity 3 years after administration	Annette von Drygalski
MPE-067	A novel gene editing lexicon strategy for the haemophilia community	Cedric Hermans
MPE-066	Improved joint health after gene therapy with Dirloctocogene Samoparvovec (SPK-8011) in people with hemophilia A	Kristen Jaworski
MPE-068	HIV comorbid Infection and etranacogene dezaparvovec therapy: efficacy and safety results from phase 2b and pivotal phase 3 HOPE-B trials 3 years after Administration	Sandra Le Quellec
PP-050	Gene Therapy Education Program - A CHS comprehensive information program	Chantal Raymond
PP-051	Gene Therapy for Hemophilia Clearing House: a single repository of resources for hemophilia	Brian O'Mahony
PP-052	The World Federation of Hemophilia Living Guidelines Model	Mona Mayla
PP-053	A conceptual roadmap to an optimal Model of Care for effective and efficient gene therapy delivery in the UK: a multi-disciplinary multi-stakeholder approach	Enrico Ferri Grazzi
PP-054	Long-term retention plan through myGTR – a patient engagement tool from World Federation of Hemophilia Gene Therapy Registry	Toong Youttananukorn
PP-055	Question and answer guide on gene therapy in hemophilia	Lourdes Pérez González
PP-056	A multi-stakeholder, collaborative approach to awareness, education and support needed in the haemophilia gene therapy patient journey: insights from a patient advisory board	Karen Pinachyan
PO-021	Improved quality of life in people with hemophilia A following gene therapy with dirloctocogene samoparvovec (SPK-8011)	Tiffany Chang
PO-023	Bioethical aspects of gene therapy in patients with hemophilia	Jorge Martin Campoy
PO-024	Patients' personal insights following a gene therapy clinical trial for hemophilia A	Shagi Galili
PO-025	ATHN transcends – hemophilia gene therapy outcomes arm: A long-term follow-up study on safety and effectiveness of gene therapy on people with hemophilia	Tammuella Chrisentery-Singleton

Health policy

POSTER #	TITLE	PRESENTING AUTHOR
PP-057	Cost of factor concentrates for low dose prophylaxis in severe phenotype hemophilia A under National Health Security Office schemes in Thailand	Bunchoo Pongtanakul
PP-058	Comparative cross-sectional study on BMI in children aged 8 to 12 years with hemophilia	Jorge Martin Campoy
PP-059	Role of a NMO in the P&R process	Miguel-Ángel Martín Domínguez
PP-060	Training of front-line healthcare professional on hereditary bleeding disorders	Sokhna Touré

Imaging

POSTER #	TITLE	PRESENTING AUTHOR
PP-061	The importance of Ultrasound as an objective method for treatment modification	Mauro Davoli
PP-062	Critical role of Ultrasonography in hemophilia patients in developing countries: Revealing the inconspicuous	Manali Bafna
PO-026	Point-of-care musculoskeletal ultrasound utilization and outcomes in a Hemophilia Treatment Center	Curtis Yee

Infectious complications

POSTER #	TITLE	PRESENTING AUTHOR
MPE-069	Epidemiological insights into hepatitis C virus infection among patients with inherited bleeding disorders: A 30-Year evolution in a brazilian cohort	Nivia Foschi

Inhibitors

POSTER #	TITLE	PRESENTING AUTHOR
PP-064	Acquired hemophilia in the postpartum period: experience from two Italian hemophilia centres	Gianluca Sottilotta
PP-065	Prediction of inhibitor risk in Hemophilia A using Machine Learning	Tiago Jose da Silva Lopes

Inhibitors

POSTER #	TITLE	PRESENTING AUTHOR
PP-066	Severe inherited hemophilia A with inhibitors combined with a platelet function disorder case from Kuwait	Hadeel mohammad
PP-067	Type 3 von Willebrand disease with inhibitors (VWD3i) – hemostatic control and transfusional complications	Catarina Camara
PO-027	Acquired hemophilia and human immunodeficiency virus: Case reports	Carole Kilach
PO-028	Management of life-threatening bleeding in a hemophilia B patient with high responder inhibitors: A case report	Te-Fu Weng
PO-029	The risk of inhibitor development can be decreased with plasma-derived von Willebrand factor containing factor VIII concentrate in previously untreated patients with hemophilia A	Aysegul Unuvar
PO-030	Successful rescue immune tolerance induction with haemate-P and emicizumab in hemophilia A patient with recurrence inhibitor post Covid-19 infection	Shin-Nan Cheng
PO-031	Inhibitor development in mild hemophilia A: four patients	Canan Albayrak

Laboratory issues

POSTER #	TITLE	PRESENTING AUTHOR
MP-025	Long-term evaluation of external quality assessment results for Factor VIII and Factor IX	Piet Meijer
MP-026	Performance control of eleven aPTT reagents for the quantification of an extended half-life factor IX	Pablo Martinez
MP-027	The use of different collagen binding assays aids in the diagnosis of von Willebrand disease	Fiona Shepherd
MPE-071	Multicenter evaluation of the haemostatic activity of emicizumab in patients with severe haemophilia A	Laurie Josset
PP-068	FVIII post infusion monitoring Survey: Results & analysis of Extended half-life (EHL) FVIII/FIX products and laboratory performance for the external quality control assessment programmes of International External Quality Assessment Scheme (IEQAS)	Anna Williams
PP-069	FVIII post infusion monitoring global study: Results & analysis of newer and extended half-life (EHL) FVIII products across external quality assessment programmes of ECAT, UK NEQAS BC & RCPAQAP	Anna Williams
PP-070	Genetic mutation of haemophilia in Singapore in relation to its severity and inhibitor	Sim Tien
PP-071	Platelet analysis by flow cytometry: EDTA or citrate sample?	Fatma Ben Lakhal

Laboratory issues

POSTER #	TITLE	PRESENTING AUTHOR
PP-072	Global comparative antithrombin (AT) field study: Impact of laboratory assay variability on the assessment of AT activity measurement	Ekta Chhabra
PP-073	Long-term performance of Factor VIII and Factor IX testing by laboratories of the Italian Hemophilia Centers	Piet Meijer
PP-074	Factor IX activity measurement of recombinant FIX Fc fusion protein eftrenonacog alfa with one-stage clotting and chromogenic substrate assay	Marie Prudkova
PP-075	Comparisons of serum osteoprotegerin (OPG) and RANKL in Children, Adolescents and Adult patients with hemophilia: are there any differences?	Aikaterini Michalopoulou
PP-076	Real world variability in drug concentration during emicizumab therapy	Susan Guy
PP-077	Pitfalls encountered during inhibitor testing in travelled samples from peripheral camps	Savitri Singh
PP-078	Discrepancies in laboratory assays for extended half-life factor VIII/Factor IX products monitoring: experience from a single pediatric center in Argentina	Rodolfo Sueldo
PP-079	Cut off for aFVIII inhibitor screening test	Rodolfo Sueldo
PO-032	F8 gene synonymous variants and their clinical correlation: our experience at La Paz University Hospital	Patricia González-Marugán

New products and novel therapies

POSTER #	TITLE	PRESENTING AUTHOR
MP-028	Dose escalation of the anti-tissue factor pathway inhibitor marstacimab in participants with severe hemophilia without inhibitors: results from the phase 3 BASIS and long-term extension trials	Andrew Palladino
MP-029	Efanesoctocog alfa treatment outcomes in subjects ≥50 years of age from the XTEND-1 trial	Johannes Oldenburg
MP-030	Reduced recovery of turoctocog alfa pegol is not always associated with antidrug antibodies against polyethylene glycol: data from three patients	Gianna Franca Rivolta
PP-080	A substudy to evaluate the feasibility and effectiveness of marstacimab administration using a prefilled pen injection device	Andrew Palladino
PP-081	ENHANCING HEMOPHILIA CARE: Experiences with Emicizumab via World Federation of Hemophilia's Humanitarian Aid Program	Masood Fareed Malik
PP-082	Prophylaxis with emicizumab in 50 children and adolescents with severe hemophilia A without inhibitor in Uruguay. National experience.	Felipe Lemos
PP-083	Evaluation of emicizumab concentration and thrombin generation in a cohort of severe hemophilia a patients with and without inhibitor during emicizumab prophylaxis.	Francesca Paoletti

New products and novel therapies

POSTER #	TITLE	PRESENTING AUTHOR
PP-084	Breaking barriers in hemophilia A care: One-year real-world experience with Emicizumab prophylaxis at Civil Service Hospital, Kathmandu, Nepal	Bishesh Sharma Poudyal
PO-033	Emicizumab prophylaxis: a single center clinical experience	Cristina Santoro
PO-034	Protein design and deep learning: A new frontier in hemophilia B management	Arthur Pimenta
PO-035	Effect of intra-articular application of Platelet Rich Plasma-Ozonated in chronic hemophilic arthropathy	Armando Hernández Salgado
PO-036	Effectiveness and safety of prophylaxis with emicizumab in Cuban patients with hemophilia A followed for two years	Dunia Castillo González
PO-037	Furniture and ludic elements design: musculoskeletal training for individuals with coagulopathies	Antonia Luque
PO-038	Fostering user-centric innovation: Target product profile for point-of-care diagnostics in resource-limited settings for hemophilia and Von Willebrand Diseases	Juliana Hagembe
PO-039	Use of mesenchymal stem cells as treatment for grade I and II hemophilic arthropathy	Scarlett Pérez Olea

Nurses' issues

POSTER #	TITLE	PRESENTING AUTHOR
MP-031	Evaluation of access to care for women/carriers of hemophilia in hemophilia treatment centres: A multinational experience	Marlène Beijlevelt
MP-032	Teaching health care staff about hemophilia: four educational resources to learn about bleeding disorders	Shamshah Aratia
MP-033	Intramuscular vs subcutaneous vaccination in children with haemophilia. Has the evidence changed since COVID19?	Charlotte Beeton
MPE-072	PRO management and collection outside clinical research: why is it so difficult?	Laura González-Rodríguez
PP-085	Western States Regional Hemophilia Network (WSRHN) nursing tele-mentoring program	Mary Lesh
PP-086	Haemophilia nurse consultant role in adult haemophilia treatment centre in South Australia – a 12 month analysis	Yu-Hsuan Lin
PP-087	Changes in the life of people with hemophilia A using emicizumab: nursing perceptions	Sonia Ferreira
PP-088	Strategies to promote autonomy in children, adolescents, and families treated with Emicizumab	Florencia Gomez

Nurses' issues

POSTER #	TITLE	PRESENTING AUTHOR
PP-089	It’s not just about the drug. Haemophilia A and the transition to Emicizumab	Jaime Chase
PP-090	The use of Peripherally Inserted Central Catheter (PICC) Line for people with haemophilia and other bleeding disorders:a single centre experience	Elsa Aradom
PO-040	Advanced practice registered nurses in coagulopathies in Spain: does it exist without a legal framework?	Sara García-Barcenilla
PO-041	Burden on parents of children with von Willebrand disease	Linda Myrin Westesson
PO-042	Nurses’ perception of their work environment in Hemophilia and Congenital Coagulopathies Units	Nuria Caballero
PO-043	Updated Nordic Haemophilia Council guidelines for the role of haemophilia nurse	Malin Axelsson
PO-044	Nurse role and systematic collection of information in the visit to the patient with hemophilia	Diego Jose Ramos Galindo
PO-045	Nursing role as coordinator in a multidisciplinary team in patients with congenital coagulopathy during elective surgeries	Gemma Guillen Peramos
PO-046	Nurse role in clinical trials of patients with congenital coagulation disorders	Diego Jose Ramos Galindo
PO-047	Manage emotions to improve adaptation to haemophilia	Alfonso Castro-Blanco
PO-048	The role of nursing in hemophilia camps	Alfonso Castro-Blanco
PO-049	Learning to self-administer treatment through play	Mª Carmen García-Rivera
PO-050	Guide to parenteral medication in Haemostasis	Sonia Herrero
PO-051	Health Improvement in an Adolescent with Type A Hemophilia using Emicizumab	Camila Stephanes

Oral health

POSTER #	TITLE	PRESENTING AUTHOR
PP-091	Cinical oral conditions in pediatric patients with inherited bleeding disorders in relation to hemorrhagic phenotype	Laura Beatriz Isidro-Olán
PO-052	Prevention from minimal invasion	Maria Mercedes Alba Bensich
PO-053	Management of combined factor I and factor VIII deficiencies: A case report with oral rehabilitation	Abdulmajeed Alrumi

Orthopedic issues

POSTER #	TITLE	PRESENTING AUTHOR
MPE-073	Functional and radiographic assessment in haemophilic arthropathy: is there a dissociation?	Rodrigo Pagnano
PP-092	Clinical features of hemophilic arthropathy of the elbow that progresses to irreversible lesions during childhood	Atsuki Yamashita
PP-093	Low bone mineral density and vitamin D deficiency in patients with hemophilia in Taiwan	Tsung-Ying Li
PP-094	World Federation of Hemophilia aid in orthopaedic surgeries: translational outcomes and real-world data from a single tertiary hemophilia care centre in India	Sandeep Pattnaik
PO-054	Heterotopic ossification in bleeding disorders: A multicenter case series	Bruno Steiner
PO-056	Platelet-Rich Plasma for chronic synovitis treatment, clinical outcomes over the years	María Landro
PO-057	Joint disease profile of cameroonian haemophiliac	Annick Ndoumba Nkengue
PO-058	Destructive arthropathy due to hemarthrosis in a patient with Glanzmann thrombasthenia. ”case report ”	Mohamed Sharif
PO-059	Treatment of hemophilic pseudotumor, with and without high-response inhibitor, report of two cases	Armando Hernández Salgado
PO-060	Safety of radiosynovectomy with Yttrium-90 and Samarium-153 in patients with haemophilia	Rodrigo Pagnano
PO-061	Patient related outcome measures in Indian hemophiliac PATIENTS after elective arthroplasty	Apeksha Kumar

Pain management

POSTER #	TITLE	PRESENTING AUTHOR
MP-034	Bridging the practice gaps in hemophilia: Usability study of HemoCopilot® a comprehensive digital self-assessment solution	Emilie Guilpain
PP-095	Perception of pain intensity in patients with hemophilia	Rafaela Pereira

Pediatrics

POSTER #	TITLE	PRESENTING AUTHOR
MP-035	Towards tailoring the use of emicizumab for hemophilia A children in China: a retrospective clinical data from a comprehensive care center of China	Qianqian Mao
MP-036	Children with bleeding disorders who developed excess weight gain during the COVID-19 pandemic revert to their pre-pandemic weight and BMI percentiles – a prospective follow-up of 76 children	Teodora Markovic
PP-096	The frequency of bleeding in pediatric patients with moderate and mild hemophilia A and B- Polish experience	Pawel Laguna
PP-097	Clinical and laboratory characteristics of children with platelet function disorders seen at a paediatric centre	Joyce Lam
PP-098	Spectrum of genetic mutations in haemophilia A and B patients at a paediatric haemophilia treatment centre in Singapore	Chiew Ying Lim
PP-099	A survey of the experiences of parents of children with severe haemophilia, recently commenced on Hemlibra	Beatrice Nolan
PP-100	The effect of the COVID-19 pandemic process on treatment compliance in hemophilia patients	Serap Karaman
PP-101	Factors related to quality of life in children with hemophilia A: a study in West Java, Indonesia	Sindy Febrianti

Physiotherapy and rehabilitation

POSTER #	TITLE	PRESENTING AUTHOR
MP-038	Hemotrack: musculoskeletal management in hemophilia with physiotherapist-driven digital solutions	Sofía Pérez-Alenda
MPE-074	Effects of resistance training on muscle strength in adults with haemophilia: a systematic review and meta-analysis	Rodrigo Núñez-Cortés
MPE-075	Enhancing hemophilia assessment and monitoring with novel digital biomarkers	Sébastien Lobet
PP-102	Characteristics and functional impairment level of persons with hemophilia with peripheral nerve injuries	Easmin Doly
PP-103	Multidisciplinary survey of hemophilia treatment in Latin America: results from 17 reference centers	Carla Daffunchio
PP-104	Physiotherapy in patients with hemophilia with virtual reality device	Cecilia Gallardo Pérez
PP-105	The Impact of dynapenia on handgrip force control in people with haemophilia	Rodrigo Núñez-Cortés

Physiotherapy and rehabilitation

POSTER #	TITLE	PRESENTING AUTHOR
PP-106	Gross motor development in infants with haemophilia. Comparisons with full-term and preterm infants of the same nationality	Dimitrios Syrengelas
PP-107	Haemophilia physiotherapy A challenge for physiotherapist - A real time experience from a developing country HTC	Dinkar Viswam
PP-108	Assesment with biopsychosocial approach in patients with hereditary bleeding disorder	Tuğçe Poyraz İşleyen
PP-109	Creating a work choice booklet: a physical therapist collaboration	Jennifer Newman
PP-110	Creating a sustainable network of physical therapists: Hemophilia Treatment Center Physical Therapy Collaborative	Jennifer Newman
PP-111	Out of the joint and into the muscle?	Bianca Da Silva
PP-112	Patients satisfaction on Rehabilitation Program (RP) in Kuressaare Hospital, Estonia	Martin Kaal
PP-113	Is ankle muscle strength correlated with performance-based outcomes such as heel rise and hop distances in monitoring the physical function of haemophilia patients?	Fırat Tan
PP-114	Monitoring people with hemophilia on low dose prophylaxis with Hemophilia joint health score	Emna Gouider
PP-115	Gene therapy for hemophilia: musculoskeletal transformations, patient experiences, and physiotherapist perspectives	Janaina Ricciardi
PP-116	Determination of cardiovascular risk in adult patients with hemophilia using the Framingham risk score and the artherosclerotic cardiovascular disease score	Aideé Conde
PP-117	Impact of physical exercise in persons with congenital coagulopathies: “Hemovement Project”	Nuria Fernandez Mosteirin
PP-118	Validation of a systematic review to evaluate the measurement properties of performance-based outcomes for the functional assessment of people with haemophilia	Catherine Holdsworth
PP-119	Evaluation of balance and proprioception in adult and paediatric haemophilia patients	Prachi Sarvaiya
PP-120	Lung function in adult hemophilia	Prachi Sarvaiya
PP-121	Joint manipulation and sliding in patients with severe hemophilia and ankle arthropathy. A controlled pilot study	Rubén Cuesta-Barriuso
PP-122	Conditioned pain modulation in patients with hemophilic arthropathy. A cross-sectional cohort study	Roberto Ucero-Lozano
PP-123	Safety and efficacy of blood flow restriction in patients with hemophilic knee arthropathy. A randomized pilot study	Elena Donoso-Úbeda

Physiotherapy and rehabilitation

POSTER #	TITLE	PRESENTING AUTHOR
PP-124	Dependence of adult patients with haemophilia on instrumental activities of daily living. A cross-sectional cohort study	Rubén Cuesta-Barriuso
PP-208	Studying the minimal clinically important difference (MCID) on physiotherapy effect for hemophilia adults with knee contracture	Lixia Chen
PP-211	Impact of contract-relax-antagonist-contract (CRAC) technique on restricted elbow extension after elbow joint bleed	Maulik Patel
PO-062	Effect of a physiotherapy exercise program on quality of life and pain in Iranian patients with severe hemophilia	Vida Marzban
PO-063	Comparative study of functional independence of hemophilia patients with restricted joint ROM over a period	Vijayakumar Narayana Pillai
PO-064	Exercise and physical conditioning in hemophilia: guidance booklets	Diogo Dias
PO-065	Joint health and treatment received in a group of patients with hemophilia A from the National Hemophilia Center Venezuela 2023	Laura Aponte
PO-067	The value of home visits during a Twinning visit	L.F.D. van Vulpen

Prophylaxis

POSTER #	TITLE	PRESENTING AUTHOR
MP-039	Preliminary results of OPG/RANKL levels in haemophilia A patients (PWHA) on emicizumab	Styliani-Despoina Christidi
MP-040	Joint health outcomes in severe haemophilia A patients on primary prophylaxis and the influence of early bleeding phenotype and treatment	Alexandros Arvanitakis
PP-125	The characteristics and treatment patterns in hemophilia B patients receiving recombinant coagulation Factor IX	Sang Kyu Park
PP-126	Racing against the odds: an analysis of prophylaxis regimens used by a severe hemophilia A marathoner	Michelle Bech
PP-127	Comparison of spontaneous bleeding incidents despite use of prophylactic factor treatments in the era of emicizumab use over 12 months for patients with moderate or severe haemophilia A in an adult haemophilia treatment centre South Australia	Yu-Hsuan Lin
PP-128	Effectiveness of starting emicizumab in routine clinical practice for patients with severe hemophilia A without FVIII inhibitor: results using picnichealth data in the US	Letizia Polito
PP-129	DIffusion of prophylaxis and introduction of innovative products in haemophilia: data from the Emilia-Romagna regional registry, 2003-2022	Gianna Franca Rivolta
PP-130	Nonacog beta pegol in adolescents and adults with hemophilia B: insights from an experience in tertiary care centre in Maharashtra	Varun Bafna

Prophylaxis

POSTER #	TITLE	PRESENTING AUTHOR
PP-131	Sixteen years real life experience of with low dose prophylaxis in a hemophilia treatment center	Ons Ghali
PP-132	First year of emicizumab prophylaxis: preliminary results of the brazilian registry of emicizumab (EMcase study)	José Sávio Santos Ferreira Filho
PP-133	Effectiveness and safety of every-5-days damoctocog alfa pegol prophylaxis in haemophilia A in phase 3, phase 4 and real-world studies	Maria Elisa Mancuso
PP-134	Bleeding episodes and surgical procedures in children and adults with haemophilia A on prophylaxis with emicizumab - the experience of a portuguese centre	Catarina Camara
PP-135	Pharmacokinetic study of fix extended half-life concentrate using differents models	Olga Benitez Hidalgo
PP-136	Transitioning from standard to extended half-life factor VIII concentrates – correlating dosing strategy with subsequent pharmacokinetic study and bleeding events	Pamela Tan
PP-137	Safety and efficacy of emicizumab in patients with severe hemophilia A and severe clinical phenotypes: retrospective data from Nigeria	Theresa Nwagha
PP-138	Use of emicizumab in patients with haemophilia A: experience from a treatment centre in Ghana West Africa	Diana Dwuma-Badu
PP-139	Achieving zero annual bleed rate with tailored prophylaxis : a retrospective observational study	Vijayakumar Narayana Pillai
PP-140	Access to prophylaxis therapy in haemophilia A: Results of the CLAHT-WFH survey for Latin-America	Jesus Ardila Novoa
PO-068	Escalating low-dose individualized haemophilia prophylaxis: a focus in China at dawn of a new era of cost effective Individualized prophylaxis	Wanru Yao
PO-069	Emicizumab prophylaxis: A novel alternative therapy for severe hemophilia A patients with and without inhibitors	Munira Borhany
PO-070	Emicizumab prophylaxis in patients with hemophilia A in China: a multicenter retrospective real-world analysis	Yuan Xu
PO-071	Paradigm shift for haemophilia prophylactic treatment in a Uruguayan adult haemophilia treatment centre	Ana Mercedes Varela Menotti
PO-072	Low dose prophylaxis in haemophilia using extended half- life factor concentrates	Tahira Zafar
PO-073	Real world experience with use of emicizumab in haemophilia A patients: case series report from Malawi	Francis Mkwenembera
PO-074	Control of haemophilia treatment with extended half-life factors in Rosario, Argentina	Mariana Raviola
PO-075	The association between factor VIII pharmacokinetic parameters and clinical outcomes: design of the MoHem 2 study	Erik Berntorp
PO-076	Relationship between adherence and pain in patients on emicizumab. Experience of a center in Rosario, Argentina	Mariela Pasquero

Prophylaxis

POSTER #	TITLE	PRESENTING AUTHOR
PO-077	Educational program for haemophilia in Gabon: development of prophylaxis for patients living with haemophilia	Stan Marc Kpumba Mihindou
PO-078	Initial experience with emicizumab prophylaxis in adults with severe haemophilia A in a Uruguayan haemophilia treatment centre	Maximiliano Berro
PO-079	Challenges and burdens of long-lasting intravenous prophylaxis in adult haemophilia patients: a study from one centre	Jelena Bodrozic

Psychosocial issues

POSTER #	TITLE	PRESENTING AUTHOR
MP-041	Gender differences in parenting stress and social support among hemophilia families	Carletha Gates
MP-042	Qualitative research to the experience and needs surrounding pregnancy and childbirth in women with von Willebrand disease	Corinne Liem
MP-043	The effects of counseling using CBT (cognitive-behavioral-therapy) on reducing irrational belief and interpersonal anxiety of hemophilic arthritis patients - comparative study of individual counseling and group counseling	Bak Sook
MP-044	Mental health and quality of life in children and adolescents living with hemophilia, a single center study in Pakistani sample	Tahira Zafar
MP-045	Training and coexistence days for children with coagulopathies in Spain	Daniel-Anibal García Diego
MP-046	Strengthening our life skills "HAVI"	David Cuartas
MP-047	Sexual dysfunction and anxiety in women with hereditary bleeding disorders	Basak Koc
MP-048	Depression among patients with hemophilia	Ana Paola Abreu Bastar
PP-141	Paternal function difficulties and hemophilia	Verónica Cerutti
PP-142	Aging with hemophilia: interviews with severe hemophilia A patients around the world	Robert Morris
PP-143	Piloting a transition readiness programme for children with haemophilia	Sheryl Seet
PP-144	Bleeding beyond the veins	Midhat Khalid
PP-145	Inclusive summer camps for children with hemophilia: 40 years of experience in the catalan association of hemophilia	Felipe Ortega
PP-146	The psychosocial aspects of hemophilia: a comprehensive study	Md. Shohanur Mithun

Psychosocial issues

POSTER #	TITLE	PRESENTING AUTHOR
PP-147	Talking with children about bleeding disorders. How to tell others	Silvina Graña
PP-148	Peers relationships. Building healthy networks	Silvina Graña
PP-149	Impact of haemophilia on family functioning	Anna-Maria Tsilia
PP-150	The Hemophilia Society of Türkiye model- newly diagnosed hemophilia family camp	Bülent Zülfikar
PP-151	Depression screening & education for patients with bleeding disorders	Denise Lowery
PP-152	Impact of the COVID-19 Pandemic on weight gain in a pediatric and adult population with bleeding disorders: a single center study	Kim Schafer
PP-153	Chess game a strategic and therapeutic paradigm for school-age individuals navigating hemophilia challenges	Geoffrey Mosongoh
PP-154	Empowering patients and families	Richa Mohan
PP-209	Psychosocial approach for tobacco addicted patients with hemophilia	Meera Hanagavadi
PO-080	Conversation circle with patients taking emicizumab: an experience report	Alice Oliver Sacramento
PO-081	Engaging with the great outdoors - a pilot project	Claire Forde
PO-082	Compartilhemos experiences: psychology – meeting of psychologists from reference teams in the care of people with hemophilia in Brazil	Diogo Dias

Quality of life/ Outcome research

POSTER #	TITLE	PRESENTING AUTHOR
MP-049	Health-Related quality of life in people with hemophilia in Italy: a single-center cross-sectional cross sectional survey	Angelo Molinari
MP-050	Mental health outcomes from the learning to live with non-severe haemophilia study: combining coreHEM mental health outlook and qualitative interviews	Simon Fletcher
MP-051	Health-Related quality of life and chronic pain burden on a cohort of people with haemophilia in 5 European countries: an updated snapshot from the cost of haemophilia in Europe: a longitudinal socio-economic survey (CHESS)	Randall Curtis

Quality of life/ Outcome research

POSTER #	TITLE	PRESENTING AUTHOR
MP-052	WiSH-QoL study – health-related quality of life (HRQoL) in adults with von Willebrand Disease (VWD) in France: Women cohort results	Annie Borel-Derlon
PP-155	Glanzmann's thrombasthenia adversely impacts psychosocial outcomes: the Glanzmann's 360 mixed methods study	Kate Khair
PP-156	Interim results from the lived experience of people with factor VII deficiency (FVIID 360) study	Kate Khair
PP-157	Development of a core outcome set for von Willebrand disease: The coreVWD initiative	Elizabeth Clearfield
PP-158	Quality of life of children, adolescents with hemophilia A and its caregivers, facing change of treatment with emicizumab. Experience in Uruguay	Felipe Lemos
PP-159	Ultrasound exam for assessment tool for joint disease within people with hemophilia	Ons Ghali
PP-160	Health-related quality of life improvements following valoctocogene roxaparvovec gene therapy in people without bleeds or target joints at baseline: a post hoc analysis from GENER8-1	Sandra Santos
PP-161	Physical functioning and pain in older men with haemophilia	Suzanne O'Callaghan
PP-162	Summary data from first collaboration of PROBE and drustvo hemofilikov slovenije – an ongoing quality of life study	Alexandra Kucher
PP-163	Beyond the bleeding: examining the health and quality of life of hemophilia A patients within ASHEMADRID	Richard Paul Habis Khoury
PP-164	Gene therapy with the Padua variant of a codon-optimized human factor IX gene etranacogene dezaparvovec in people with hemophilia B: effects on patient-oriented outcomes measured using the patient reported outcomes, burdens and experiences (PROBE) questionnaire in the HOPE-B study	Mark Skinner
PP-165	PROBE: Brazil data	Tania Pietrobelli
PP-166	QOL improvement project for adult hemophilia patients using smart watch	Seung Geun Kim
PP-167	National member organization's PROBE data dashboard update – adding a pain dashboard page for better understanding of the pain impact in people with hemophilia	Alexandra Kucher
PP-168	An innovative approach to helping people living with rare bleeding disorder (RBD) to initiate and retounr to behaviours that promote joint health	Sophie Ayçaguer
PP-169	Quality of life (QoL) of people with hemophilia (PwH) in Madagascar	Olivat Aimée Rakoto Alson
PP-170	Health-related quality of life and its associated factors among hemophilia patients: experience from Ethiopian hemophilia treatment centre	Tamrat Tadesse

Quality of life/ Outcome research

POSTER #	TITLE	PRESENTING AUTHOR
PP-171	Characteristics of the health-related quality of life in patients with severe hemophilia A treated with Emicizumab at the National Institute of Hematology and Blood Transfusion (NIHBT) in 2021	Mai Nguyen
PP-172	The quality of life among hemophilia patients in South Kalimantan, Indonesia	Wulandewi Marhaeni
PO-083	Hemophilia Treatment on demand versus prophylaxis on health related quality of life	Dinkar Viswam
PO-085	WFH-HUMANITARIAN AID: “Enhancing the quality of life for persons with bleeding disorders in Pakistan	Shahla Tariq Sohail
PO-086	Burden of disease and impact on quality of life in hereditary factor X deficiency patients who have experienced menorrhagia	Kim Clark
PO-087	Burden of disease and impact on quality of life in hereditary factor X deficiency patients receiving prophylaxis	Kim Clark
PO-088	EMICIZUMAB: Reshaping Lives	Ayisha Imran
PO-089	Health-related quality-of-life, treatment burden and preference in patients with haemophilia: Results from the concizumab phase 3 explorer7 & 8 studies	Gary Benson
PO-090	Living with Hemophilia in Latin America: An evaluation of youth development interventions to improve quality of life	Deniece Chevannes
PO-091	Considerations of health factors among hemophilia patients over different periods, aiming to meticulously trace the historical shifts in their priorities	chang jihoon
PO-092	Treatment-related clinical and humanistic unmet needs in haemophilia A without inhibitors	Amy Shapiro
PO-093	SEEK – sharing experience, expanding knowledge: A digital platform for patient-driven research in bleeding disorders	Luke Pembroke
PO-094	Evaluation of health-related quality of life in adolescents and adults with hemophilia treated in a rehabilitation unit	Aideé Conde
PO-095	Evaluation of quality of life in patients with Von Willebrand Disease in a health institution in Colombia	Juan Wilches
PO-096	Hemophilia and phisical activity: impact of sport on the quality of life of people with hemophilia	Carlos Pemán Asín
PO-097	Addressing iron deficiency anemia in bleeding disorder patients: Lessons from a single center perspective	Munira Borhany
PO-098	Health-related quality of life among children and adolescent patients with hemophilia: a study in Argentinian population	Maria Arrieta
PO-099	Comparative study on health-related quality of life in children and adolescents with hemophilia in Argentina	Maria Arrieta
PO-125	Hemophilia B patient journey	Tania Pietrobelli

Rare bleeding disorders

POSTER #	TITLE	PRESENTING AUTHOR
MP-053	The needs of people living with extremely rare bleeding disorders and bleeding disorders of unknown cause	Maja Johanne Søndergaard Knudsen
MP-054	A unique case of recurrent venous thromboembolism in severe factor XIII deficiency	L.F.D. van Vulpen
MPE-076	Generation of a viable mouse model of factor V deficiency: a mild disease phenotype	Andrea Miguel-Batuecas
MPE-077	HMB-001: A Phase 1/2, first-in-human study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy in participants with Glanzmann Thrombasthenia	Jigar Amin
PP-173	Perioperative management of a series of patients with hereditary factor X deficiency	Diana Patiño-Culma
PP-174	Cardiovascular risk factors profile in adult patients with haemophilia in Morocco	Mouad Lamtai
PP-175	Acquired hemophilia A in Portugal in the last 18 years – the experience of the 5 haemophilia centres	Cristina Catarino
PP-176	Intracranial hemorrhage in children with hemophilia : a 7-years retrospective study in a single-center in Indonesia	Novie Amelia Chozie
PP-177	Impact of the G403T mutation in coagulation factor XI deficiency: insights from a southern Tunisia patient cohort	Maha Charfi
PO-100	Diagnosing and treating bleeding disorder of unknown cause (BDUC): an illustrated review on current practice and future directions (BDUC-iN study group and SYMPHONY consortium)	Amaury Monard
PO-101	Long term reductions in haemarthrosis in Boys with severe haemophilia A: results of a three years follow up study on the China haemophilia secondary individualized prophylaxis study (CHIPS)	Qianqian Mao
PO-102	Glanzmann Thrombasthenia: identification of two novel mutations in Tunisia	Emna Gouider
PO-103	Evaluation of thromboelastometry, thrombin generation assay and bleeding score in patients with hereditary factor VII and factor XI deficiency	Petr Smejkal
PO-104	Future of hemophilia patient registries: A pioneering initiative in the UAE	Muhammad Faisal Khanani
PO-105	Management of acquired hemophilia A cases using emicizumab and immunosuppressive therapy: A case-series	Varun Bafna
PO-106	Safety and efficacy of long-term treatment of type 1 plasminogen deficiency patients with intravenous plasminogen replacement therapy	Karen Thibaudeau
PO-107	An overview of Glanzmann Thrombasthenia in Portugal	Sara Morais

Rare bleeding disorders

POSTER #	TITLE	PRESENTING AUTHOR
PO-108	Constitutional thrombopathies : the first 7 cases diagnosed in sub-Saharan Africa	Sokhna Touré
PO-109	Glanzmann's thrombasthenia and meningioma: a neurosurgical journey	Filipa Pires
PO-110	ATHN transcends: Natural history cohort study of bleeding symptoms and treatment outcomes in patients with Glanzmann Thrombasthenia	Michael Recht

Surgical treatment

POSTER #	TITLE	PRESENTING AUTHOR
MP-055	Haemophilic elbow arthropathy treated with arthroscopic synovectomy - a haemophilia tertiary centre experience	Rory Hammond
PP-178	Enhancing hemostasis in severe hemophiliacs with rheumatic heart disease: A pilot study on comprehensive surgical management	Shruti Mishra
PP-179	Lower doses of bypass agents achieve satisfactory haemostasis during major surgery in patients with haemophilia and inhibitors	Aby Abraham
PO-111	Surgical outcomes for people living with hemophilia in a resource constrained setting	Carole Kilach
PO-112	Managing surgical procedures in children with inherited bleeding disorders; a single center experience	Nita Radhakrishnan
PO-113	WFH Humanitarian Aid Program: expanded support for hemophilia care in Enugu, Nigeria	Theresa Nwagha

Trials in progress

POSTER #	TITLE	PRESENTING AUTHOR
PO-114	Development of a comprehensive questionnaire to assess disease awareness in people with hemophilia	Mariela Pasquero

Von Willebrand disease

POSTER #	TITLE	PRESENTING AUTHOR
MP-056	Comparing DDAVP response classifications in 149 children with von Willebrand disease	Michael Shu
PP-180	VWDtest.com continues promoting global awareness of von Willebrand disease	Fernando Corrales-Medina
PP-181	Spectrum of bleeding manifestations in patients with type 3 von Willebrand disease	Dinesh Chandra

Von Willebrand disease

POSTER #	TITLE	PRESENTING AUTHOR
PP-182	Assessment of ISTH-BAT score in von Willebrand disease patients	Agoritsa Varaklioti
PP-183	Assessing the hemostatic effect of factor replacement therapies under blood flow conditions in Von Willebrand disease	Elena G Arias-Salgado
PP-184	Validation of a rapid diagnostic approach in inherited and acquired defects of VWF by automatic tests assessed before and after DDAVP trial: Results from the Chinese-Italian CREWILACT study	Augusto B Federici
PO-115	Paediatric population with moderate or severe von Willebrand disease in Sweden	Linda Myrin Westesson
PO-116	Digital therapeutic education program for people concerned by Von Willebrand disease	Nicolas Guerin
PO-117	Management of patients with monoclonal gammopathy of undetermined significance and acquired von Willebrand disease	Gianluca Sottilotta
PO-118	Real-world efficacy and safety of plasma-derived von Willebrand factor-containing FVIII concentrates in patients with Von Willebrand Disease in Italy: the RECLASFAWILL study	Augusto B Federici
PO-119	Safety and efficacy of the use of Fanhdi® in patients with von Willebrand disease: a prospective, observational, post-authorization study	Alejhandra Lei
PO-120	Clinical, biochemical, and molecular characterization of Mexican patients with von Willebrand disease	Ana Jaloma-Cruz
PO-121	Long-term monitoring and multidisciplinary management of abnormal uterine bleeding in teenagers with type 3 von Willebrand disease	Novie Amelia Chozie

Women and girls' health and research

POSTER #	TITLE	PRESENTING AUTHOR
MP-057	Evaluation of bleeding score in haemophilia carriers	Gabriela Sliba
MP-058	Development of two unmet needs assessment tools for young women with a bleeding disorder and heavy menstrual bleeding	Jaime Chase
MP-060	Hemophilia carriers in Tunisia: Where are we?	Fatma Ben Lakhal
MP-061	Factor VIII level in mothers of patients with severe hemophilia A and its impact on bleeding and joint status	Azza Tantawy
MP-062	Needs of women and girls with coagulopathies in Spain	Lourdes Pérez González
MP-063	Use of recombinant von Willebrand factor concentrate for peri-partum haemostatic management of women with type 2 VWD; a case series	Ozlem Turan

Women and girls' health and research

POSTER #	TITLE	PRESENTING AUTHOR
PP-185	Females with Von Willebrand disease: The silent majority in Brazil	Yara Pires
PP-186	Significance of joint ultrasound examination in a medical check-up for hemophilic carriers	Teruhisa Fujii
PP-187	Creating a multidisciplinary supporting group for female hemophilia carriers	Patricia Cabré
PP-188	Abnormal haemostasis and bleeding problems seen in possible carriers of haemophilia A: a pilot study	Taiwo Kotila
PP-189	Characterization of hemostasis disorders in patients with menorrhagia	Dunia Castillo González
PP-190	Changing perspectives about women in bleedings disorders community, role and participation	Amanda Brito del Pino Mouro
PP-191	The accurate classification of women with hemophilia and the importance of genetic studies.	Liliana Rossetti
PP-192	Reasons for consultation among women and girls with bleeding disorders in Venezuela: review of the last two years	Apsara Boadas
PP-193	Prevalence of unmet needs among adolescent females with a bleeding disorder and heavy menstrual bleeding	Janis Chamberlain
PP-194	Semiological assessment and use of scales in patients with excessive menstrual bleeding in primary care: a pending task	Bolivar Luis Diaz Jordan
PP-195	Women diagnosed with postpartum hemophilia, more than an anecdotal fact: Retrospective analysis in a single center	Bolivar Luis Diaz Jordan
PP-196	Once upon a time… UNSEEN LIFE: Stories of women carriers of hemophilia in Latin America	Maria Robert
PP-197	Update on the diagnosis of haemophilia carrier women: experience from a centre	Daniela Neme
PP-198	Trauma and taboo. Family story of women with bleeding disorder in Poland	Bernadetta Pieczyńska
PP-199	Commission of women with coagulopathies of the Spanish federation of hemophilia (Fedhemo)	Laura Quintas-Lorenzo
PP-200	Findings from the WFH NMO survey on women and girls with bleeding disorders	Salome Mekhuzla
PP-201	Women with hereditary bleeding disorders in a sub-Sahara African setting	Diariatou Sy
PP-202	Menorrhagia in adolescent girls with underlying bleeding disorders; effect of a low cost intervention	Nita Radhakrishnan
PP-212	Women with low rate hemophilia A carrier or severe von Willebrand disease: how facing up in low-income countries?	Laurent Frenzel
PO-122	Trauma and taboo. Family story of WBD in 20th century Poland	Bernadetta Pieczyńska
PO-123	Phenotype assessment and genetic study to the detection of Haemophilia B carriers	Maria Veronica Arrieta
PO-124	A case series of girls with hemophilia A	Fitri Primacakti

Case studies demonstrating best practices

POSTER #	TITLE	PRESENTING AUTHOR
LBA-PP-001	Hemophilia care management at a blood center in northeastern Brazil: patient-centered outcomes	Tatyane Oliveira Rebouças
LBA-PP-002	Variant pHis118Arg in a patient with Severe Hemophilia A determines the presence of a mild phenotype	Gisela Barros Garcia
LBA-PP-003	Replacement therapy outcomes in patients with haemophilia receiving antithrombotic therapy	Matteo Di Minno
PO-126	Prevalence of depression amongst adult hemophilia patients registered with Hemophilia Foundation of Zambia	Dhruv Darji
PO-127	Effective perioperative management of a patient with acquired Von Willebrand Syndrome in Wilms' Tumor: A case report and literature review	Chonlatis Srichumpuang
PO-128	Experiences in dentistry surgeries of greater complexity in patients with hemophilia A and B in province of Salta, Argentina	Maria Sol Cruz
PO-129	Clinical outcomes of total knee arthroplasty in patients with hemophilic arthropathy – a prospective study	Marc Isler
PO-130	LADIES: Bleeding disorders in women - Health care and support	Mariana Battazza
PO-131	Successful removal of high titer inhibitor in a patient with hemophilia A by low dose rituximab combined with low dose FVIII immune tolerance therapy	Li Zhou
PO-132	Enhanced immunotherapy yields superior efficacy in patients with high-titer acquired hemophilia A	Li Zhou
PO-133	Transfusion-related immunomodulation in patients with Hemophilia	Katsiaryna Kabayeva
PO-134	Correlation between age at diagnosis with clinical and joint health outcomes in patients with severe and moderate haemophilia at Kenyatta National Hospital	Anastasia Khasiani
PO-135	A case series of the first under 5-year old patients with severe hemophilia A after using Emicizumab at the largest Children’s Hospital of Panama	Kenia Miller
PO-136	Degree of overload in primary caregivers of patients with hemophilia. Preliminary results.	Ezequiel Martinez Martinez
PO-137	Optimizing joint health in hemophilia patients: Insights from a retrospective cohort study	Susan Halimeh
PO-138	Incidence and prevalence trends of hemophilia and complications in Armenia: A comprehensive 13-year retrospective analysis (2010-2022)	Heghine Khachatryan
PO-139	Challenges in the diagnosis and management of rare coagulation disorders in a country in crisis.	Roula Farah

Clinical trials (in progress)

POSTER #	TITLE	PRESENTING AUTHOR
PO-140	Analysis of the musculoskeletal profile of patients with hemophilia, evaluated by the physiotherapy sector, at the Belo Horizonte blood center of the Hemominas foundation	Alice Oliver Rosa Sacramento
PO-141	Investigation of the impact of medication and social characteristics on the mental health of hemophiliac in specific regions of China	Li Zhou

Novel therapies

POSTER #	TITLE	PRESENTING AUTHOR
LBA-PP-004	Multicenter retrospective and prospective analysis of Emicizumab and FVIII prophylaxis in children with severe hemophilia A	Tamer Hassan
LBA-PP-005	Effectiveness of kinesiologic taping on function and pain in patients with Hemophilia A	Elif Kazanci
PO-142	The changing paradigm of severe haemophilia A management in East Mediterranean: A survey from haemophilia treatment centres in the region	Mohsen Elalfy
PO-143	Mental health art contest for adolescents with heavy menstrual bleeding – a quality improvement initiative	Sabrina Farina
PO-144	Experience with joint health scores in hemophilia as a tool for evaluating results in emicizumab prophylaxis	Tatyane Oliveira Rebouças